Entrada Therapeutics (NASDAQ:TRDA) COO Sells $40,570.32 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan Dowden sold 3,116 shares of the business’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $13.02, for a total transaction of $40,570.32. Following the transaction, the chief operating officer owned 210,482 shares of the company’s stock, valued at $2,740,475.64. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Entrada Therapeutics Stock Performance

NASDAQ:TRDA opened at $12.69 on Friday. The firm’s fifty day moving average is $11.34 and its two-hundred day moving average is $8.94. The firm has a market cap of $485.77 million, a price-to-earnings ratio of -3.67 and a beta of -0.12. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $13.65.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The business had revenue of $1.30 million during the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. As a group, equities research analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TRDA. Oppenheimer initiated coverage on Entrada Therapeutics in a research report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price target for the company. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Finally, Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.50.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TRDA. Russell Investments Group Ltd. lifted its stake in Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after buying an additional 3,707 shares in the last quarter. State of Wyoming increased its stake in Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after buying an additional 4,295 shares in the last quarter. AXQ Capital LP purchased a new stake in Entrada Therapeutics during the 3rd quarter worth approximately $67,000. Occudo Quantitative Strategies LP acquired a new position in shares of Entrada Therapeutics during the second quarter valued at approximately $68,000. Finally, Inscription Capital LLC purchased a new position in shares of Entrada Therapeutics in the third quarter valued at approximately $69,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.